average tirzepatide dose for weight loss Zepbound (Tirzepatide) Dosage Guide Tirzepatide dosing guide with chart

BMO Capital Markets analyst Etzer Darout in a note to investors said that AstraZeneca believes that AZD5004 is differentiated from other GLP-1 therapies in development and on the market, particularly given its favorable tolerability. Further helping AZD5004 distinguish itself in the crowded obesity space is its reduction in glucose and body weight in patients with type 2 diabetes and its simplified manufacturing path, Darout wrote

Staying within personal use boundaries and avoiding commercial activity or medical claims keeps researchers on the right side of these boundaries

The trial data show how the two regimens compare across different weight loss targets: Source: Wharton S et al

Consistent access to therapy is also essential, as interruptions can worsen GI symptoms and reduce adherence